Showing 10,581 - 10,600 results of 48,875 for search '(( a ((((laser decrease) OR (mean decrease))) OR (linear decrease)) ) OR ( a largest decrease ))', query time: 1.10s Refine Results
  1. 10581
  2. 10582
  3. 10583
  4. 10584
  5. 10585
  6. 10586
  7. 10587
  8. 10588
  9. 10589
  10. 10590
  11. 10591

    Cytisine significantly decreased sucrose intake in rats consuming sucrose short-term (4 weeks) and long-term (12 weeks) using the intermittent-access two-bottle choice paradigm. by Masroor Shariff (2583442)

    Published 2016
    “…<p>Cytisine (4 mg/kg) significantly decreased sucrose consumption (Fig 3A and 3B) after the onset of drinking in short-term (4 weeks) and long-term (12 weeks) sucrose exposure rats. …”
  12. 10592

    Mecamylamine significantly decreased sucrose intake in rats consuming sucrose short-term (4 weeks) and long-term (12 weeks) using the intermittent-access two-bottle choice paradigm... by Masroor Shariff (2583442)

    Published 2016
    “…<p>Mecamylamine (2 mg/kg) significantly decreased sucrose consumption in short-term (4 weeks) and long-term (12 weeks) sucrose exposure rats (Fig 2A and 2B). …”
  13. 10593
  14. 10594

    Demographic data of patients with POAG and OHT. by Chareenun Chirapapaisan (8843843)

    Published 2024
    “…In total, 28 eyes were included in the study, with a mean patient age of 65.71±10.2 years. After IOP reduction, all biometric parameters, except CCT and ACD, exhibited a decrease without reaching statistical significance (all p>0.05). …”
  15. 10595
  16. 10596

    Participant and lab results flow. by Gad Murenzi (6243719)

    Published 2025
    “…</p><p>Results</p><p>Women included in this analysis (N = 4,880) had a mean age of 40 years, > 98% were on antiretroviral therapy, and 61% had a CD4 count of ≥500 cells/µL. …”
  17. 10597
  18. 10598
  19. 10599
  20. 10600

    Raw data. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”